RESOLUTE

Research Empowerment on Solute Carriers

An imaging-based assay for a challenging target: the case of SLC30A8

Lucia Azzollini ¹, Dolores Del Prete ¹, Christoph Klimek ², Gernot Wolf ², Alvaro Ingles-Prieto ², Lia Scarabottolo ¹

¹ Axxam S.p.A., OpenZone, Bresso (Milan, Italy)

² CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Introduction

• SLC30A8 (or Zinc Transporter 8) is expressed at a high level only in the pancreas,



- especially in insulin-producing beta cells
- it is a zinc transporter involved in the accumulation of zinc from the cytoplasm into intracellular vesicles
- it is involved in intracellular zinc homeostasis and signalling through compartmentation of the ion and regulation of its concentration
- it is thought to be required for providing zinc to allow for proper maturation, storage and secretion of insulin
- diseases associated with SLC30A8 include Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus 5

Figure 1 – *Solute carrier family 30 (zinc transporter), member 8.*

An imaging cell-based assay was successfully developed in 384-well plate format:

SLC

SLC30A1 yes

• Cell line: HEK-293 Jump In T-REX/SLC30A8 WT or SLC30A8 D110N_D224N (OE cell lines from CeMM, HA-tagged SLC; IF expression confirmed)

• Read-out: Zinc (Zn²⁺) influx measurements using a Zinc-sensitive fluorescent dye (Fluo Zin-3, AM, cell permeant, by ThermoFisher)

Immunofluorescence for cellular localization of SLC30A8 WT and SLC30A8 D110N_D224N over-expressed in HEK293 Jump-In T-REx cell line

HEK-293 Jump In T-REx SLC30A8 WT

HEK JumpIn T-REx SLC30A8 D110N_D224N

Ubiquitous endogenous expression of Zinc transporters

(SLC30 and SLC39 families)

The endogenous expression of different Zinc transporters both in HEK293 and other cell lines makes SLC30A8 characterization very challenging due to high unspecific





Both	SLC30A8	and
SLC30A8	D110N_	D224N
are parti	ally localiz	zed in
plasma	mer	nbrane
(localizati	on also in	the ER
and Golgi)	

Figure 2 – Merge images of staining with: HA antibody for SLC30A8 wt and D110N_D224N mutant (green), SLC1A5 antibody for plasma membrane (red), nuclei (blue). Images were generated by CeMM.

SLC30A10	yes	
SLC30A2	no	
SLC30A3	yes	
SLC30A4	yes	
SLC30A5	yes	
SLC30A6	yes	
SLC30A7	yes	
SLC30A8	no	
SLC30A9	yes	
SLC39A1	yes	
SLC39A10	yes	
SLC39A11	yes	
SLC39A12	no	
SLC39A13	yes	
SLC39A14	yes	
SLC39A2	no	
SLC39A3	yes	
SLC39A4	yes	
SLC39A5	no	
SLC39A6	yes	
SLC39A7	yes	
SLC39A8	yes	
SLC39A9	yes	

HEK293 JumpIn cell line

Endogenous expression

background

	Endogenous expression in RESOLUTE cell lines					
SLC IT	LS180 -	HCT116 🔽	HuH-7 🔽	1321-N1 🔽	MDA-MB-4(-	SK-MEL-28 🔽
SLC30A1	12.6	6.7	11.6	21.0	11.4	19.9
SLC30A10	0.0	0.1	23.6	0.0	0.0	5.3
SLC30A2	0.2	0.1	0.2	0.1	0.3	0.1
SLC30A3	0.1	13.3	0.5	6.6	0.2	0.5
SLC30A4	0.6	1.3	0.3	1.8	2.3	2.4
SLC30A5	43.6	43.1	38.3	23.1	42.5	51.9
SLC30A6	14.9	22.8	16.5	31.4	25.4	22.0
SLC30A7	12.1	10.1	11.0	19.6	13.5	19.2
SLC30A8	0.0	0.0	0.0	0.0	0.0	0.0
SLC30A9	66.4	42.2	37.0	25.9	38.8	31.9
SLC39A1	89.2	60.2	101.3	119.0	200.9	103.8
SLC39A10	57.2	18.7	13.2	15.4	6.3	24.3
SLC39A11	13.6	39.1	25.7	24.8	55.0	48.1
SLC39A12	0.0	0.0	0.0	0.0	0.0	0.7
SLC39A13	10.6	13.9	18.8	37.2	15.5	30.5
SLC39A14	98.8	142.8	554.2	209.7	25.6	197.3
SLC39A2	0.0	0.0	0.1	0.0	1.7	0.0
SLC39A3	57.4	53.1	51.5	72.2	44.4	78.1
SLC39A4	111.9	103.3	4.3	10.8	32.5	9.9
SLC39A5	2.5	0.2	112.0	0.4	0.1	0.2
SLC39A6	40.8	92.7	29.1	25.4	22.4	77.2
SLC39A7	23.1	19.2	27.4	22.6	24.7	21.7
SLC39A8	30.3	14.9	7.5	7.1	20.5	17.5
SLC39A9	48.7	44.6	38.5	33.9	33.2	25.1

Figure 3 – Information from Resolute WP1 dashboard

Imaging-based high-content analysis of SLC30A8

HEK JumpIn T-REx HEK JumpIn T-REx HEK JumpIn SLC30A8 WT SLC12A6 (unr

HEK JumpIn T-REx • (SLC12A6 (unrelated)



Figure 4

side)



- Cells induction: 24h (1 µg/mL doxycycline)
- Fluorescent dye loading: 45 mins at 37°C (in Ca²⁺ -Mg²⁺ -phosphate-free HBSS w 5mM EDTA)
- Automatic washing (3X) w

Imaging-based high-content analysis of SLC30A8 WT versus SLC30A8 D110N_D224N double mutant



HEK JumpIn T-REx SLC30A8 D110N_D224N ind



SLC30A8
 Asp110/Asp224
 mutations
 resulted in a
 reduction of Zn²⁺



FluoZin-3, 1 mM ZnCl₂

Zinc dose-response on induced cell lines

stimulation of induced cells with 1 mM ZnCl₂ (upper side); dose-

response curves expressed as percentage of Zinc positive cells (lower

- Representative images of FluoZin-3 staining after

Ca²⁺ -Mg²⁺ -phosphate-free HBSS

- Stimulation w Zn²⁺ doseresponse (as Zinc Chloride) up to 5 mM
- Reading at Operetta CLS (PerkinElmer)

 Zn²⁺ D/R: Zinc internalization was increased in induced SLC30A8 compared to unrelated transporter (SLC12A6) or WT cell line



FluoZin-3, 1 mM ZnCl₂



Figure 5 – Representative images of FluoZin-3 staining after stimulation of induced cells with 1 mM ZnCl₂ (upper side); dose-response curves expressed as percentage of Zinc positive cells (lower side)



 Same protocol described for Figure 4 applied for imaging

•	Zn ²⁺ D/R: Z	Zinc inter	nalization
	was increa	nsed in	induced
5	SLC30A8	WT	in
	compariso	n to	induced
	SLC30A8	D110N_	_D224N;
	significant o	lifference	between
	induced S	LC30A8	WT and
	uninduced	conditio	n

efpia innovative medicines initiative

The RESOLUTE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 777372. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This poster reflects only the authors' views and neither IMI nor the European Union and EFPIA are responsible for any use that may be made of the information contained therein.

www.re-solute.eu lucia.azzollini.la@axxam.com